Home » Newsletters » BioWorld Science

BioWorld Science

April 3, 2018

View Archived Issues

FN-1501 identified as a novel FLT-3 and CDK inhibitor for the treatment of AML

NIAID initiates phase I study of HIV-1 vaccines

GSK initiates phase II study of SARM GSK-2881078 in patients with COPD

Shanghai Pharmaceuticals initiates phase Ia trial with B-001 in patients with NHL

Insmed submits NDA for ALIS for nontuberculous mycobacterial lung disease

FDA grants orphan drug designation to Scholar Rock's SRK-015 for SMA

Catalyst submits NDA for Firdapse for LEMS

Pharmacokinetics of anti-HIV agent GS-9131 explored in phase I study

European Commission approves expanded indication for Xgeva

EMA accepts cemiplimab MAA for cutaneous squamous cell carcinoma

Symic reports 12-month data from SHIELD trial of SB-030 in peripheral vascular disease

EMA accepts Dupixent submission in asthma

First phase I data presented for ACT-709478 in healthy volunteers

ETC-206, a new agent for hematological cancers

FDA grants accelerated approval to Blincyto for B-cell precursor ALL with minimal residual disease

Numerate patents novel FFAR4 agonists

Roche and Genentech divulge new JAK1 inhibitors

Calithera Biosciences identifies new CD73 inhibitors

FDA approves Leukine for H-ARS

Chinese researchers discover CDK4/6 inhibitors

Novartis targets kinetoplastid proteasome for Chagas disease, leishmaniasis

Sunovion submits NDA for APL-130277 to treat off episodes associated with Parkinson's disease

Albert Einstein College of Medicine patents MSC-derived microvesicles

Motif Bio initiates rolling NDA for iclaprim

Compugen and MedImmune sign cancer immunotherapy license agreement

FDA issues refusal to file letter for Alkermes' ALKS-5461 NDA

Taiwan Liposome submits IND for TLC-590

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...